TRIM21 and dermatomyositis: In a cluster analysis study by Xu et al. on anti-MDA5 + DM patients, the cluster with a high RP-ILD risk was more likely to include patients with both anti-Ro-52 antibodies and high anti-MDA5 antibody titers and had the highest mortality rates [57].